Please assess the completion status of the following clinical trial:

Trial Title: Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H. pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H. pylori-eradication therapy~* ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 7-day quadruple therapy (Type: EXPERIMENTAL): 1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days,~4. metronidazole 500 mg twice daily for 7 days
- 10-day sequential therapy (Type: EXPERIMENTAL): 1. pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~2. pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days.
- 7-day standard triple therapy (Type: ACTIVE_COMPARATOR): 1. pantoprazole 40 mg twice daily for 7 days,~2. clarithromycin 500 mg twice daily for 7 days,~3. amoxicillin 1 g twice daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).